18F-FDG positron-emission tomography/computed tomography findings of radiographic lesions suggesting old healed tuberculosis

Journal of Korean Medical Science

Volumn 29, Issue 3, 2014, Pages 386-391

  Jeong, Yun Jeong ^a   Paeng, Jin Chul ^b   Nam, Hyun Yeol ^b,c   Lee, Ji Sun ^b   Lee, Sang Min ^b   Yoo, Chul Gyu ^b   Kim, Young Whan ^b   Han, Sung Koo ^b   Yim, Jae Joon ^b  

^a Dongguk University Ilsan Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Interferon gamma release tests; Latent tuberculosis; Positron emission tomography; Tomography, X Ray computed; Tuberculosis, pulmonary

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; CROSS-SECTIONAL STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MALE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; RISK; RISK FACTOR; TUBERCULIN TEST; TUBERCULOSIS; VERY ELDERLY;

INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TUBERCULOSIS, PULMONARY;

ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; INTERFERON-GAMMA RELEASE TESTS; MALE; MIDDLE AGED; ODDS RATIO; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84908378311     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2014.29.3.386     Document Type: Article

References (34)

1. Kumar V, Abbas AK, Fausto N, Mitchell R. Robbins basic pathology. 8th ed. Philadelphia: Saunders Elsevier, 2007, p516-22.
2. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350: 2060-7.
3. Knight SB, Delbeke D, Stewart JR, Sandler MP. Evaluation of pulmonary lesions with FDG-PET: comparison of findings in patients with and without a history of prior malignancy. Chest 1996; 109: 982-8.
4. Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick MP. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules: potential role in evaluation and management. Chest 1993; 104: 997-1002.
5. Basu S, Saboury B, Werner T, Alavi A. Clinical utility of FDG-PET and PET/CT in non-malignant thoracic disorders. Mol Imaging Biol 2011; 13: 1051-60.
6. Ichiya Y, Kuwabara Y, Sasaki M, Yoshida T, Akashi Y, Murayama S, Nakamura K, Fukumura T, Masuda K. FDG-PET in infectious lesions: the detection and assessment of lesion activity. Ann Nucl Med 1996; 10: 185-91.
7. Shim SS, Lee KS, Kim BT, Choi JY, Chung MJ, Lee EJ. Focal parenchymal lung lesions showing a potential of false-positive and false-negative interpretations on integrated PET/CT. AJR Am J Roentgenol 2006; 186: 639-48.
8. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33: 1972-80.
9. Jones HA, Clark RJ, Rhodes CG, Schofield JB, Krausz T, Haslett C. In vivo measurement of neutrophil activity in experimental lung inflammation. Am J Respir Crit Care Med 1994; 149: 1635-9.
10. Brudin LH, Valind SO, Rhodes CG, Pantin CF, Sweatman M, Jones T, Hughes JM. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 1994; 21: 297-305.
11. Yang CM, Hsu CH, Lee CM, Wang FC. Intense uptake of [F-18]-fluoro-2 deoxy-D-glucose in active pulmonary tuberculosis. Ann Nucl Med 2003; 17: 407-10.
12. Bakheet SM, Powe J, Ezzat A, Rostom A. F-18-FDG uptake in tuberculosis. Clin Nucl Med 1998; 23: 739-42.
13. Yen RF, Chen ML, Liu FY, Ko SC, Chang YL, Chieng PU, Su CT. False-positive 2-[F-18]-fluoro-2-deoxy-D-glucose positron emission tomography studies for evaluation of focal pulmonary abnormalities. J Formos Med Assoc 1998; 97: 642-5.
14. Knopp MV, Bischoff HG. Evaluation of pulmonary lesions with positron emission tomography. Radiologe 1994; 34: 588-91.
15. Goo JM, Im JG, Do KH, Yeo JS, Seo JB, Kim HY, Chung JK. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 2000; 216: 117-21.
16. Kim IJ, Lee JS, Kim SJ, Kim YK, Jeong YJ, Jun S, Nam HY, Kim JS. Double-phase 18F-FDG PET-CT for determination of pulmonary tuberculoma activity. Eur J Nucl Med Mol Imaging 2008; 35: 808-14.
17. Hahm CR, Park HY, Jeon K, Um SW, Suh GY, Chung MP, Kim H, Kwon OJ, Koh WJ. Solitary pulmonary nodules caused by Mycobacterium tuberculosis and Mycobacterium avium complex. Lung 2010; 188: 25-31.
18. Park IN, Ryu JS, Shim TS. Evaluation of therapeutic response of tuberculoma using F-18 FDG positron emission tomography. Clin Nucl Med 2008; 33: 1-3.
19. Martinez V, Castilla-Lievre MA, Guillet-Caruba C, Grenier G, Fior R, De-sarnaud S, Doucet-Populaire F, Boué F. (18)F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response. Int J Tuberc Lung Dis 2012; 16: 1180-5.
20. Martinez VN, Komatsu NK, De Figueredo SM, Waldman EA. Equity in health: tuberculosis in the Bolivian immigrant community of São Paulo, Brazil. Trop Med Int Health 2012; 17: 1417-24.
21. Linh NN, Marks GB, Crawford AB. Radiographic predictors of subsequent reactivation of tuberculosis. Int J Tuberc Lung Dis 2007; 11: 1136-42.
22. Targeted tuberculin testing and treatment of latent tuberculosis infection: this official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999: this is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC): this statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161: S221-47.
23. Yu CH, Wang T, Sun YE, Yao SL, Tian JH, Yin DY. Fluorine-18 fluorodeoxyglucose uptake in patients with benign pulmonary nodules. Zhonghua Wai Ke Za Zhi 2006; 44: 90-2.
24. Ernst JD. The immunological life cycle of tuberculosis. Nat Rev Immunol 2012; 12: 581-91.
25. Gill WP, Harik NS, Whiddon MR, Liao RP, Mittler JE, Sherman DR. A replication clock for Mycobacterium tuberculosis. Nat Med 2009; 15: 211-4.
26. Ford CB, Lin PL, Chase MR, Shah RR, Iartchouk O, Galagan J, Mohaideen N, Ioerger TR, Sacchettini JC, Lipsitch M, et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 2011; 43: 482-6.
27. Horsburgh CR Jr, O'Donnell M, Chamblee S, Moreland JL, Johnson J, Marsh BJ, Narita M, Johnson LS, von Reyn CF. Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med 2010; 182: 420-5.
28. Stead WW, Lofgren JP. Does the risk of tuberculosis increase in old age? J Infect Dis 1983; 147: 951-5.
29. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3: S231-79.
30. Cao JP, Zhang LY, Zhu JQ, Chin DP. Two-year follow-up of directly-observed intermittent regimens for smear-positive pulmonary tuberculosis in China. Int J Tuberc Lung Dis 1998; 2: 360-4.
31. Thomas A, Gopi PG, Santha T, Chandrasekaran V, Subramani R, Selvakumar N, Eusuff SI, Sadacharam K, Narayanan PR. Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India. Int J Tuberc Lung Dis 2005; 9: 556-61.
32. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial: International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982; 60: 555-64.
33. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008; 177: 1164-70.
34. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 2012; 142: 63-75.